Abstract: Inhibitors against SARS-COV-1, SARS-CoV-2 (Covid-19), MERS-CoV, and variants within each, including methods of treating a subject suffering from such respiratory disease.

Abstract: Antiviral drugs targeting the N-terminal domain (NTD) of the spike receptor binding domain (RBD) and methods of treating a subject suffering from coronavirus.

Abstract: Antiviral drugs targeting the N-terminal domain (NTD) of the spike receptor binding domain (RBD) and methods of treating a subject suffering from coronavirus.

Abstract: Inhibitors against SARS-COV-1, SARS-CoV-2 (Covid-19), MERS-CoV, and variants within each, including methods of treating a subject suffering from such respiratory disease.

Abstract: Disclosed herein are compounds, compositions and methods for preventing, reducing or inhibiting an amount of protein tyrosine phosphatase receptor type C (CD45) expressed or activity of CD45 in a cell or a subject. Also disclosed are methods for preventing, inhibiting or treating an infection in a cell or a subject immunizing a subject or enhancing a subject's immune response against an infection preventing, reducing or inhibiting the susceptibility of a cell or a subject to an infection or subsequent pathogenesis and morbidity due to the infection and preventing, reducing, and inhibiting apoptosis caused by or resulting from a biological agent in a cell or a subject which comprises preventing, reducing or inhibiting an amount of protein tyrosine phosphatase receptor type C (CD45) expressed or activity of CD45 in the cell or the subject.

Abstract: Disclosed herein are methods of inhibiting, reducing or preventing growth of or destroying bacteria of at least one bacterial strain which comprises contacting the bacteria with the compounds disclosed herein. Also disclosed are methods of treating, inhibiting or preventing an infection or intoxication caused by bacteria of at least one bacterial strain in a subject and pharmaceutical and cosmetic compositions comprising the compounds disclosed herein.

Abstract: Disclosed herein is a pharmacophore model for inhibiting anthrax lethal factor protease activity which comprises a first aromatic center A, a second aromatic center B, a first polar center C, a second polar center D, a third polar center E, and a neutral linker F. In some embodiments, the distance between the first aromatic center A and the neutral linker F is about 4.7 to about 6.7 ?, preferably about 5.7 ?. In some embodiments, the distance between the neutral linker F and the second aromatic center B is about 3.4 to about 4.4 ?, preferably about 3.9 ?. In some embodiments, the distance between first aromatic center A and the first polar center C is about 5.5 to about 7.5 ?, preferably about 6.5 ?. In some embodiments, the distance between the first aromatic center A and the second polar center D is about 4.6 to about 6.6 ?, preferably about 5.6 ?. In some embodiments, the distance between the second aromatic center B and the second polar center D is about 3.6 to about 4.6 ?, preferably about 4.1 ?.

Abstract: An inactive pore-forming agent which is activated to lytic function by a condition such as pH, light, heat, reducing potential, or metal ion concentration, or substance such as a protease, at the surface of a cell.